Biotech's wellspring: a survey of the health of the private sector

Journal name:
Nature Biotechnology
Volume:
30,
Pages:
395–400
Year published:
DOI:
doi:10.1038/nbt.2209
Published online

An examination of the private biotech industry reveals shrinking financial resources and higher hurdles to obtain funding, but new models are evolving to meet the challenge.

At a glance

Figures

  1. Global venture funding of private biotech companies, 2001-2011.
    Figure 1: Global venture funding of private biotech companies, 2001–2011.

    Source: BioWorld (Atlanta).

  2. Venture capital investment for biotechnology therapeutic companies.
    Figure 2: Venture capital investment for biotechnology therapeutic companies.

    (a) Investment in 2007–2011. (b) Investment in 2011 by quarter in the US. (c) Investment by region. Source: Dow Jones VentureSource.

  3. Top university patent assignees.
    Figure 3: Top university patent assignees.

    Source: IP Checkups.

Author information

Affiliations

  1. Brady Huggett is Nature Biotechnology's Business Editor.

Author details

Supplementary information

Excel files

  1. Supplementary Text and Figures (66 KB)

    Supplementary Figure 1 and Supplementary Tables 1-8

Additional data